Takahide Nejo, MD, PhD
Research Interest
Takahide Nejo, MD, PhD is a physician-scientist, currently working as a postdoctoral scholar in the laboratory of Dr. Hideho Okada at the UCSF Brain Tumor Center (BTC). Through his over 10-year career as a board-certified neurosurgeon, he has been motivated by the demand for breakthrough therapeutics for glioma and the potential of cancer immunotherapy. In his PhD training, he carried out immunogenomics-based research with an interest in the analysis of tumor neoantigens. On the basis of the genomic and transcriptomic analyses on primary and recurrent paired clinical samples, the study elucidated an immune evasion mechanism through reduced neoantigen expression during tumor progression. With the enthusiasm for antigen discovery and the development of effective cancer immunotherapy for gliomas, he joined the Okada lab in January 2019. Since then, he has worked on transcriptomic and proteomic analyses in collaboration with multidisciplinary research groups beyond the BTC.
Outside the lab: Marathon, Traveling, Hiking, and Skiing (with his wife and two daughters)
Email: takahide.nejo@ucsf.edu
Twitter: https://twitter.com/TakahideNejo
2009, MD, Tokyo Medical and Dental University, School of Medicine, Japan
2011, Junior Resident (Rotating Internship), Tokyo Metropolitan Police Hospital, Japan
2015, Residency Program, Department of Neurosurgery, The University of Tokyo, Japan
2019, PhD, The University of Tokyo, Graduate School of Medicine, Japan
2019-present, Postdoctoral Scholar, Department of Neurological Surgery, UCSF
2017, Best paper award of the year from the Department of Neurosurgery, The University of Tokyo
2018, AACR Scholar-in-Training Award (AACR Special Conference on CNS Immunobiology)
2018, JSPS Research Fellowships for Young Scientists, Doctoral Course Students (DC2)
2019, TOYOBO Biotechnology foundation long-term research grant
2020, JSPS Overseas Research Fellowships
2022, Basic Science Award (2022 SNO Annual Meeting)
2023, Young Investigator Award (2023 SITC Annual Meeting)
Glioma-neuronal circuit remodeling induces regional immunosuppression.
Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H.
bioRxiv. August 6 2023. doi: 10.1101/2023.08.04.548295. (not peer-reviewed)
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H.
J Clin Invest. 2022 Feb 1;132(3):e151239. doi: 10.1172/JCI151239. PMID: 34882581; PMCID: PMC8803342.
The current state of immunotherapy for primary and secondary brain tumors – similarities and differences.
Nejo T, Mende A, Okada H.
Jpn J Clin Oncol. 2020 Oct 22;50(11):1231-1245. doi: 10.1093/jjco/hyaa164.
H3.3K27M peptide vaccine in diffuse midline glioma: a PNOC report.
Mueller S, Taitt J, Villanueva-Meyer J, … Nejo T, … Butterfield L, Prados M, Okada H.
J Clin Invest. (2020) Aug 20;140378. PMID: 32817593. doi: 10.1172/JCI140378.
Tumor Antigens in Glioma.
Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H.
Semin Immunol. (2020) Feb;47:101385. PMID: 32037183. doi:10.1016/j.smim.2020.101385.
Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Nejo T, Matsushita H, Karasaki T, … Mukasa A, Saito N, Kakimi K.
Cancer Immunol Res. (2019) Jul;7(7):1148-1161. PMID: 31088845. doi:10.1158/2326-6066.CIR-18-0599.
A complete list of the published work can be found here:
My Bibliography: https://pubmed.ncbi.nlm.nih.gov/?term=takahide%20nejo&sort=date
Google Scholar: https://scholar.google.com/citations?user=1ol49kIAAAAJ&hl=en